HCG — Research Dossier
Evidence grading
FDA status
Approved
Ovulation induction / hypogonadism / cryptorchidism
Weight-loss evidence
None
FDA label: not effective for obesity
OTC HCG products
Banned 2011
FDA & FTC declared fraudulent and illegal
Mechanism
LH-receptor
Glycoprotein — stimulates gonadal steroidogenesis
HCG is an established reproductive hormone with legitimate approved uses — and the subject of one of the most thoroughly debunked diet claims in modern medicine.
Human chorionic gonadotropin (HCG) is a glycoprotein hormone produced by the placenta during pregnancy. It acts on luteinising-hormone receptors to stimulate gonadal steroidogenesis. As an injectable medicine it is FDA-approved for certain forms of anovulatory female infertility (ovulation induction), for male hypogonadotropic hypogonadism, and for prepubertal cryptorchidism not due to anatomical obstruction.
“HCG has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. There is no substantial evidence that it increases weight loss beyond caloric restriction, improves fat distribution, or reduces hunger.”
— FDA HCG prescribing information
Approved indications
FDA-approved uses of injectable HCG are limited to: ovulation induction in anovulatory infertility (in conjunction with gonadotrophins); male hypogonadotropic hypogonadism; and prepubertal cryptorchidism not due to anatomical obstruction. Each indication is supported by a defined evidence base and requires medical supervision.
The weight-loss claim — what the evidence shows
The "HCG diet" pairs HCG with an extreme low-calorie regimen (often around 500 kcal/day). The evidence is consistent and negative:
- The FDA drug label states plainly that HCG has not been demonstrated to be effective adjunctive therapy in the treatment of obesity, and that there is no substantial evidence it increases weight loss beyond caloric restriction, improves fat distribution, or reduces hunger.
- A criteria-based meta-analysis of 24 studies (Lijesen et al., 1995) found no scientific evidence that HCG is effective for weight loss, fat redistribution, hunger, or well-being.
- Any weight lost on the protocol is attributable to the severe calorie restriction, which itself carries risks including malnutrition, electrolyte imbalance, and gallstones.
Regulatory action on weight-loss products
In 2011 the FDA and FTC jointly declared over-the-counter HCG weight-loss products fraudulent and illegal, sending warning letters to manufacturers. The FDA simultaneously required that all prescription HCG labelling include a statement that HCG has not been demonstrated effective for weight loss. This regulatory action reflects the totality of the evidence, not a precautionary position.
What this evidence is — and isn’t
These trials studied pharmaceutical-grade HCG administered under medical supervision in controlled settings. The figures summarised in this dossier describe that published science only.
They are not outcomes associated with research-grade material, and not results attributable to any use of the product sold in this catalogue. Nothing here is an endorsement, recommendation, or instruction for human use.
See also
References
- 1
Lijesen GKS, Theeuwen I, Assendelft WJJ, Van Der Wal G. The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis. Br J Clin Pharmacol. 1995.
- 2
U.S. Food and Drug Administration. Human Chorionic Gonadotropin (HCG) — Prescribing Information. FDA / Various manufacturers 2024.
- 3
U.S. Food and Drug Administration / Federal Trade Commission. Warning letters and consumer update on over-the-counter HCG weight-loss products. FDA / FTC 2011.
Research & Laboratory Use Only
This dossier is compiled for research planning and educational purposes only. It summarises published scientific literature and does not constitute medical advice, dosing guidance, or a therapeutic claim. All Nexyra Lab products are for research purposes only and are not for human or veterinary use. Nothing in this document should be interpreted as recommending, endorsing, or facilitating the self-administration of any compound.
A one-time legal review of this template and disclaimer is recommended before the Journal section is made publicly accessible, given the health-adjacent nature of this content.